Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GLSI Stock Forecast 2026-2027
$18.57
Current Price
$272.57M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GLSI Price Targets
+169.3%
To High Target of $50.00
+155.8%
To Median Target of $47.50
+142.3%
To Low Target of $45.00
GLSI Price Momentum
0.0%
1 Week Change
-22.8%
1 Month Change
+71.8%
1 Year Change
-11.6%
Year-to-Date Change
-45.5%
From 52W High of $34.10
+138.7%
From 52W Low of $7.78
📊 TOP ANALYST CALLS
Did GLSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Greenwich LifeSciences is one of their latest high-conviction picks.
Latest GLSI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, GLSI has a bullish consensus with a median price target of $47.50 (ranging from $45.00 to $50.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $18.57, the median forecast implies a 155.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 169.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLSI Analyst Ratings
2
Buy
0
Hold
0
Sell
GLSI Price Target Range
Low
$45.00
Average
$47.50
High
$50.00
Current: $18.57
Latest GLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $50.00 |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 20, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 1, 2021 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jan 27, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| Jan 26, 2021 | Aegis Capital | Buy | Initiates | $N/A |
Greenwich LifeSciences Inc. (GLSI) Competitors
The following stocks are similar to Greenwich LifeSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GLSI
Greenwich LifeSciences
mkt cap
290.63M
Greenwich LifeSciences Inc. (GLSI) Financial Data
Greenwich LifeSciences Inc. has a market capitalization of $272.57M with a P/E ratio of -13.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -676.7%.
Valuation Metrics
Market Cap
$272.57M
Enterprise Value
$280.12M
P/E Ratio
-13.0x
PEG Ratio
-0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+3.9%
Current Ratio
2.0x
Debt/Equity
0.0x
ROE
-676.7%
ROA
-211.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Greenwich LifeSciences Inc. (GLSI) Business Model
About Greenwich LifeSciences Inc.
What They Do
Develops cancer immunotherapies targeting HER2-positive cancers.
Business Model
Greenwich LifeSciences Inc. operates as a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. The company generates revenue by advancing its lead product candidate, GLSI-100, through clinical trials, particularly targeting patients at high risk of breast cancer recurrence. Success in these trials could lead to partnerships, licensing agreements, or eventual commercialization of its therapies.
Additional Information
Founded in 2006 and based in Stafford, Texas, the company is currently conducting the Flamingo-01 Phase III clinical trial, enrolling up to 750 patients across the U.S. and Europe. Their approach aims to fill significant gaps in existing cancer treatment options, especially for HER2-positive patients who have undergone standard therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Snehal S. Patel
Country
United States
IPO Year
2020
Website
greenwichlifesciences.comGreenwich LifeSciences Inc. (GLSI) Latest News & Analysis
Latest News
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) is conducting a Phase III trial, FLAMINGO-01, for its breast cancer immunotherapy GLSI-100, with updates on GP2's commercial use in Europe.
Why It Matters
Greenwich LifeSciences' update on its Phase III trial for GLSI-100 signals progress in cancer treatment, potentially impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is conducting a Phase III trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. They updated their Form 10-K for FY 2025.
Why It Matters
Greenwich LifeSciences' Phase III trial update and 10-K filing indicate progress in its cancer treatment, potentially impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
1 month ago
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) presented results from its Phase III FLAMINGO-01 trial on GLSI-100, an immunotherapy for breast cancer, at the ASCO Annual Meeting 2026.
Why It Matters
Greenwich LifeSciences' Phase III trial results for GLSI-100 could significantly impact stock performance and market sentiment, influencing investment decisions in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
1 month ago
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) is non-compliant with Nasdaq rules due to a missed quarterly report. However, trading continues unaffected on the Nasdaq Capital Market.
Why It Matters
Greenwich LifeSciences faces compliance issues with Nasdaq due to late financial filings, signaling potential operational or financial instability that could affect stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
2 months ago
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) is non-compliant with Nasdaq rules due to not filing its 2025 Annual Report. This notice does not currently affect its stock listing or trading.
Why It Matters
Greenwich LifeSciences' failure to file its 10-K raises concerns about financial transparency and compliance, potentially impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Greenwich LifeSciences (Nasdaq: GLSI) announced acceptance of an abstract and poster presentation for its Phase III trial of GLSI-100 at the 2026 ASCO Annual Meeting.
Why It Matters
The acceptance of Greenwich LifeSciences' abstract for the ASCO meeting signals potential validation of their immunotherapy, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GLSI Stock
What is Greenwich LifeSciences Inc.'s (GLSI) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Greenwich LifeSciences Inc. (GLSI) has a median price target of $47.50. The highest price target is $50.00 and the lowest is $45.00.
Is GLSI stock a good investment in 2027?
According to current analyst ratings, GLSI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLSI stock?
Wall Street analysts predict GLSI stock could reach $47.50 in the next 12 months. This represents a 155.8% increase from the current price of $18.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Greenwich LifeSciences Inc.'s business model?
Greenwich LifeSciences Inc. operates as a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. The company generates revenue by advancing its lead product candidate, GLSI-100, through clinical trials, particularly targeting patients at high risk of breast cancer recurrence. Success in these trials could lead to partnerships, licensing agreements, or eventual commercialization of its therapies.
What is the highest forecasted price for GLSI Greenwich LifeSciences Inc.?
The highest price target for GLSI is $50.00 from Yi Chen at HC Wainwright & Co., which represents a 169.3% increase from the current price of $18.57.
What is the lowest forecasted price for GLSI Greenwich LifeSciences Inc.?
The lowest price target for GLSI is $45.00 from at , which represents a 142.3% increase from the current price of $18.57.
What is the overall GLSI consensus from analysts for Greenwich LifeSciences Inc.?
The overall analyst consensus for GLSI is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $47.50.
How accurate are GLSI stock price projections?
Stock price projections, including those for Greenwich LifeSciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 9:40 AM UTC